This trial compares two surgical procedures for reducing the risk of ovarian cancer in women with BRCA1 mutations.
1 Primary · 7 Secondary · Reporting Duration: Up to 20 years
Active Control
Experimental Treatment
2262 Total Participants · 2 Treatment Groups
Primary Treatment: Bilateral Salpingectomy · No Placebo Group · N/A
Age 35 - 50 · Female Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Alberta | 100.0% |
18 - 65 | 100.0% |
Did not meet criteria | 100.0% |